AAAAAA

   
Results: 1-7 |
Results: 7
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms
Authors: Bantar, C Nicola, F Canigia, LF Arenoso, HJ Soutric, J Montoto, M Blanco, M Smayevsky, J Jasovich, A
Citation: C. Bantar et al., Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms, J CHEMOTHER, 13(4), 2001, pp. 402-406
Limits of aortic stop flow infusion chemotherapy in the treatment of advanced cancer
Authors: Zanon, C Goss, M Nicola, F Alabiso, O Zai, S Aymele, AG Castagneto, B Grosso, M Mancini, A Gazzera, C Pacitti, A Martina, G Vaj, M Mattalia, A
Citation: C. Zanon et al., Limits of aortic stop flow infusion chemotherapy in the treatment of advanced cancer, PANMIN MED, 43(4), 2001, pp. 243-248
A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections
Authors: Bantar, C Nicola, F Canigia, LF Arenoso, HJ Soutric, J Montoto, M Blanco, M Smayevsky, J Jasovich, A
Citation: C. Bantar et al., A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections, J CHEMOTHER, 12(3), 2000, pp. 223-227
Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains
Authors: Bantar, C Di Chiara, M Nicola, F Relloso, S Smayevsky, J
Citation: C. Bantar et al., Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains, DIAG MICR I, 37(1), 2000, pp. 41-44
Comparison of several methods to determine methicillin-resistance in Staphylococcus aureus with focus on borderline strains
Authors: Nicola, F Bantar, C Canigia, LF Relloso, S Bianchini, H Smayevsky, J
Citation: F. Nicola et al., Comparison of several methods to determine methicillin-resistance in Staphylococcus aureus with focus on borderline strains, DIAG MICR I, 36(2), 2000, pp. 91-93
Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections
Authors: Bantar, C Durlach, R Nicola, F Freuler, C Bonvehi, P Vazquez, R Smayevsky, J
Citation: C. Bantar et al., Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections, J ANTIMICRO, 43(5), 1999, pp. 737-740
Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli
Authors: Bantar, C Nicola, F Arenoso, HJ Galas, M Soria, L Dana, D Rossi, A Bianchini, H Jasovich, A
Citation: C. Bantar et al., Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli, ANTIM AG CH, 43(6), 1999, pp. 1503-1504
Risultati: 1-7 |